Cargando…

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response

The molecular heterogeneity of gene expression profiles of glioblastoma multiforme (GBM) are the most important prognostic factors for tumor recurrence and drug resistance. Thus, the aim of this study was to identify potential target genes related to temozolomide (TMZ) resistance and GBM recurrence....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Justin Bo-Kai, Lee, Tzong-Yi, Cheng, Sho-Jen, Lee, Gilbert Aaron, Chen, Yung-Chieh, Le, Nguyen Quoc Khanh, Huang, Shiu-Wen, Kuo, Duen-Pang, Li, Yi-Tien, Chang, Tzu-Hao, Chen, Cheng-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625522/ https://www.ncbi.nlm.nih.gov/pubmed/34834399 http://dx.doi.org/10.3390/jpm11111047

Ejemplares similares

Radiomic Immunophenotyping of GSEA-Assessed Immunophenotypes of Glioblastoma and Its Implications for Prognosis: A Feasibility Study
por: Hsu, Justin Bo-Kai, et al.
Publicado: (2020)

Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
por: Lee, Gilbert Aaron, et al.
Publicado: (2021)

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Identification of potential biomarkers related to glioma survival by gene expression profile analysis
por: Hsu, Justin Bo-Kai, et al.
Publicado: (2019)

Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
por: Wei, Kuo-Chen, et al.
Publicado: (2013)

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression
por: Yang, Jen-Tsung, et al.
Publicado: (2023)

Personalized Prediction of Postconcussive Working Memory Decline: A Feasibility Study
por: Chen, Yung-Chieh, et al.
Publicado: (2022)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2021)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide
por: CHEN, CHIEN-MIN, et al.
Publicado: (2015)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Machine learning-based segmentation of ischemic penumbra by using diffusion tensor metrics in a rat model
por: Kuo, Duen-Pang, et al.
Publicado: (2020)

Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
por: Tseng, Wei-Lung, et al.
Publicado: (2017)

Diffusion Tensor-Derived Properties of Benign Oligemia, True “at Risk” Penumbra, and Infarct Core during the First Three Hours of Stroke Onset: A Rat Model
por: Chiu, Fang-Ying, et al.
Publicado: (2018)

Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells
por: Cheng, Shu-Yu, et al.
Publicado: (2021)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Differentiation of the Infarct Core from Ischemic Penumbra within the First 4.5 Hours, Using Diffusion Tensor Imaging-Derived Metrics: A Rat Model
por: Kuo, Duen-Pang, et al.
Publicado: (2017)

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
por: Gong, Lingli, et al.
Publicado: (2022)

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
por: Wang, Yu, et al.
Publicado: (2017)

Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation
por: Tsai, Yu-Ting, et al.
Publicado: (2022)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis
por: Chen, Tzu-Chi, et al.
Publicado: (2019)

Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase
por: Chang, Kwang-Yu, et al.
Publicado: (2017)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era
por: Paravati, Anthony J., et al.
Publicado: (2010)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
por: Tsai, Yu-Ling, et al.
Publicado: (2020)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

GADD45A plays a protective role against temozolomide treatment in glioblastoma cells
por: Wang, Hsiao-Han, et al.
Publicado: (2017)

Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
por: Woo, Jong-Yun, et al.
Publicado: (2015)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

Interplay of m(6)A and histone modifications contributes to temozolomide resistance in glioblastoma
por: Li, Fuxi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_be4etjlish24g8t8ilf41hsan0